Purpose

This study sought to determine genetics and oncology specialists’ views of integrating BRCA1 and BRCA2 testing in epithelial ovarian and breast cancer into routine practice.

Methods

Qualitative interviews were designed using the Consolidated Framework for Implementation Research. Questions included experiences or views of the BRCA testing processes, implementation needs of oncology health professionals, perceived challenges, and future ideas for interventions to integrate genetic testing into oncology.

Results

Twenty-two participants were interviewed from twelve health organizations and four themes were identified: (1) embracing the shift to mainstream genetic testing, with the majority of participants viewing BRCA testing as clinically useful and routine use important for maintaining a patient centered process; (2) the need for communication networks and role delineation to integrate routine genetic testing; (3) factors that influence sustaining routine genetic testing, including ongoing training, resources and funding, real-world adaptation, system complexity, and champions; and (4) variation in system interventions for integrating routine genetic testing align to organizational context.

Conclusion

Findings illustrate the need for integrating genetic testing into routine oncology, and that adaptation of interventions and processes is essential to sustain a feasible model. An understanding of individual and organizational implementation factors will help to prepare for future integration of routine genetic testing in other cancers.

中文翻译：

---

澳大利亚如何将常规基因测序整合到肿瘤学中：通过实施科学镜头进行的定性研究。

目的

本研究旨在确定遗传学和肿瘤学专家将BRCA1和BRCA2检测在上皮性卵巢癌和乳腺癌中纳入常规实践的观点。

方法

定性访谈是使用实施研究综合框架设计的。问题包括BRCA检测过程的经验或观点、肿瘤学卫生专业人员的实施需求、感知到的挑战以及将基因检测整合到肿瘤学中的干预措施的未来想法。

结果

来自 12 个卫生组织的 22 名参与者接受了采访，并确定了四个主题：(1) 接受向主流基因检测的转变，大多数参与者认为BRCA检测在临床上有用且常规使用对于维持以患者为中心的过程很重要；(2) 需要沟通网络和角色描述来整合常规基因检测；(3) 影响维持常规基因检测的因素，包括持续的培训、资源和资金、现实世界的适应、系统复杂性和拥护者；(4) 用于整合常规基因检测的系统干预的变化与组织环境保持一致。

结论

研究结果表明需要将基因检测整合到常规肿瘤学中，并且干预措施和流程的调整对于维持可行的模型至关重要。了解个人和组织实施因素将有助于为将来在其他癌症中整合常规基因检测做准备。